Mixed set of financials from Gilead Sciences

2 February 2022
gilead-big

US biotech Gilead Sciences (Nasdaq: GILD) announced its financial results for the fourth quarter and full year 2021 after markets closed on Tuesday.

Total fourth quarter 2021 revenue of $7.2 billion decreased 2% compared to the same period in 2020, due to decreased demand for COVID-19 antiviral Veklury (remdesivir), partially offset by favorable pricing dynamics in HIV. However, total sales beat consensus forecast of $6.7 billion. Gilead’s shares fell 3.1% to $66.30 after-hours, but edged back 3.6% to $66.00 in pre-market trading today.

Diluted earnings per share (EPS) plunge to $0.30 for the fourth quarter 2021 compared to $1.23 for the same period in 2020. Non-generally accepted practice (GAAP) diluted EPS decreased to $0.69 for the fourth quarter 2021 compared to $2.19 for the same period in 2020, well below the $1.59 expected by FactSet.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology